The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX)

The antimetabolites 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of children's acute lymphoblastic leukemia (ALL). The biochemical mechanisms underlying the increased therapeutic efficacy of the combination of these drugs have not yet been elu...

Full description

Saved in:
Bibliographic Details
Published in:General pharmacology 1999-10, Vol.33 (4), p.341-346
Main Authors: Giverhaug, Trude, Loennechen, Thrina, Aarbakke, Jarle
Format: Article
Language:English
Subjects:
6-Mercaptopurine
Antimetabolites, Antineoplastic - metabolism
Antimetabolites, Antineoplastic - pharmacokinetics
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Child
Drug Interactions
Humans
Interaction
Medical sciences
Mercaptopurine - metabolism
Mercaptopurine - pharmacokinetics
Mercaptopurine - therapeutic use
Methotrexate
Methotrexate - metabolism
Methotrexate - pharmacokinetics
Methotrexate - therapeutic use
Pharmacology. Drug treatments
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The antimetabolites 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of children's acute lymphoblastic leukemia (ALL). The biochemical mechanisms underlying the increased therapeutic efficacy of the combination of these drugs have not yet been elucidated. However, both drugs interact with important pathways, such as purine de novo synthesis (PDNS), purine salvage, and methylation reactions. A review of the mechanistic aspects of the interactions between 6-MP and MTX is given.
ISSN:0306-3623
1879-0011
DOI:10.1016/S0306-3623(99)00022-1